Bellicum Pharmaceuticals Inc BLCM:NASDAQ

Last Price$1.84NASDAQ Previous Close - Last Trade as of 12:59PM ET 11/26/21

Today's Change0.00(0.00%)
Bid (Size)$1.69 (6)
Ask (Size)$1.85 (35)
Day Low / High$1.75 - 1.85
Volume73.6 K

View Biotechnology IndustryPeer Comparison as of 11/26/2021


Bellicum Pharmaceuticals Inc ( NASDAQ )

Price: $1.84
Change: 0.00 (0.00%)
Volume: 73.6 K
12:59PM ET 11/26/2021

InVivo Therapeutics Holdings Corp ( NASDAQ )

Price: $0.55
Change: -0.004 (0.79%)
Volume: 1.1 M
1:00PM ET 11/26/2021

Xenetic Biosciences Inc ( NASDAQ )

Price: $1.46
Change: -0.02 (1.69%)
Volume: 85.6 K
12:58PM ET 11/26/2021

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Histogen Inc ( NASDAQ )

Price: $0.53
Change: +0.003 (0.67%)
Volume: 705.4 K
1:00PM ET 11/26/2021

Read more news Recent News

Bellicum Pharmaceuticals, MD Anderson Cancer Center Enter Licensing Deal on CaspaCIDe Safety Switch
9:59AM ET 9/01/2021 MT Newswires

Bellicum Pharmaceuticals (BLCM) said Wednesday it entered a global licensing deal with the University of Texas MD Anderson Cancer Center for certain...

Bellicum Signs Deal License Deal With UNC Lineberger, Massachusetts General Hospital
9:14AM ET 6/28/2021 MT Newswires

Bellicum Pharmaceuticals (BLCM) said Monday it has signed a licensing deal with the University of North Carolina Lineberger Comprehensive Cancer Center and...

-- Earnings Flash (BLCM) BELLICUM PHARMACEUTICALS Reports Q4 Revenue $500,000
4:08PM ET 3/30/2021 MT Newswires


Corcept Therapeutics Names CFO
5:50AM ET 3/02/2021 MT Newswires

Corcept Therapeutics (CORT) has appointed Atabak Mokari chief financial officer, succeeding Charles Robb who became chief business officer. Mokari served...

Company Profile

Business DescriptionBellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. View company web site for more details
Address3730 Kirby Drive
Houston, Texas 77098
Number of Employees173
Recent SEC Filing11/04/20218-K
President, Chief Executive Officer & DirectorRichard A. Fair
Senior Vice President & Head-ResearchAaron Foster
Vice President-Viral Vector DevelopmentJoseph Howard Senesac

Company Highlights

Price Open$1.78
Previous Close$1.84
52 Week Range$1.66 - 8.15
Market Capitalization$15.5 M
Shares Outstanding8.4 M
SectorHealth Technology
Next Earnings Announcement03/29/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.48
Beta vs. S&P 500N/A
Revenue$1.1 M
Net Profit Margin-79.13%
Return on Equity-64.60%

Analyst Ratings as of 02/26/2021

Consensus RecommendationConsensus Icon
Powered by Factset